Compare Gilead Sciences, Inc. (GILD) vs Strategy Inc. (MSTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Strategy Inc. — how do they compare? Gilead Sciences, Inc. trades at $136 (market cap $168.35B), while Strategy Inc. trades at $97 (market cap $37.84B). The key difference: Gilead Sciences, Inc. is far larger — about 4.4× Strategy Inc.'s market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Strategy Inc. pays none. Which is the better fit depends on your goals.
| GILD | MSTR | |
|---|---|---|
Market Cap | $168.35B | $37.84B |
Sector | Health | Technology |
52-Week High | $155.80 | $394.39 |
52-Week Low | $110.56 | $82.31 |
Enterprise Value | $191.42B | $56.61B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
MSTR trades at $97.33, down 2.68% on the day, with a bearish technical signal and weak fundamentals including a negative net income margin of -6,102.96% and three consecutive quarterly earnings misses. The company's performance remains heavily influenced by its Bitcoin holdings, with recent news highlighting Bitcoin sales to fund stock buybacks and address capital structure concerns.
The outlook is mixed: analyst consensus is bullish with a $210 price target, but high leverage, volatile Bitcoin exposure, and persistent losses pose significant risks. Investment appeal hinges on Bitcoin's recovery and management's ability to stabilize finances, making it speculative for equity investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →
